Lipid metabolism and neuroinflammation in alzheimer's disease: A role for liver X receptors

Endocrine Reviews

Volumn 33, Issue 5, 2012, Pages 715-746

  Kang, Jihong ^a   Rivest, Serge ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Université Laval   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CHOLESTEROL; GLUCOSE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; CELL LEVEL; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE TARGETING; GENETIC RISK; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; INSULIN RESISTANCE; LIGAND BINDING; LIPID METABOLISM; LIPOGENESIS; MOLECULAR PATHOLOGY; MOLECULAR SENSOR; NERVOUS SYSTEM INFLAMMATION; NIEMANN PICK DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CHOLESTEROL; HUMANS; INFLAMMATION; ORPHAN NUCLEAR RECEPTORS;

EID: 84870783499     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2011-1049     Document Type: Review

References (354)

1. Hardy J, Selkoe DJ. 2002 The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. 2011 Alzheimer's disease. Lancet 377:1019-1031
3. Tanzi RE, Bertram L. 2005 Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120: 545-555
4. Small SA, Duff K. 2008 Linking Aβ and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60:534-542
5. Hardy J. 2006 Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 3:71-73
6. Cole SL, Vassar R. 2007 The Alzheimer's disease β-secretase enzyme, BACE1. Mol Neurodegener 2:22
7. Vetrivel KS, Zhang YW, Xu H, Thinakaran G. 2006 Pathological and physiological functions of presenilins. Mol Neurodegener 1:4
8. Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, Schweighoffer F, Désiré L. 2008 Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 106:392-404
9. ChoiYH, YonGH, HongKS, YooDS, ChoiCW, ParkWK, Kong JY, Kim YS, Ryu SY. 2008 In vitro BACE-1 inhibitory phenolic components from the seeds of Psoralea corylifolia. Planta Med 74:1405-1408
10. Laras Y, Garino C, Dessolin J, Weck C, Moret V, Rolland A, Kraus JL. 2009 New N(4)-substituted piperazine naphthamide derivatives as BACE-1 inhibitors. J Enzyme Inhib Med Chem 24:181-187
11. Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, Shearman MS. 2004 Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 279:43419-43426
12. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L, Kirby L, RoviraMB, Forette F, Orgogozo JM. 2005 Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64: 1553-1562
13. Meraz-Ríos MA, Lira-De León KI, Campos-Peña V, De Anda-Hernández MA, Mena-López R. 2010 Tau oligomers and aggregation in Alzheimer's disease. J Neurochem 112: 1353-1367
14. Takashima A. 2010 TAUaggregation is a therapeutic target for Alzheimer's disease. Curr Alzheimer Res 7:665-669
15. Balaraman Y, Limaye AR, Levey AI, Srinivasan S. 2006 Glycogen synthase kinase 3β and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol Life Sci 63:1226-1235
16. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M. 2011 Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression. J Biol Chem 286: 34457-34467
17. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN. 2004 Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 23:159-169
18. Tabet N, Feldman H. 2002 Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev 2:CD003673
19. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. 2000 Statins and the risk of dementia. Lancet 356:1627-1631
20. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD. 2006 Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6:246-254
21. Gold M, Alderton C, Zvartau-Hind M, Egginton S, Saunders AM, Irizarry M, Craft S, Landreth G, Linnamägi U, Sawchak S. 2010 Rosiglitazone monotherapy in mild-tomoderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 30:131-146
22. Hauptmann S, Scherping I, Dröse S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, Müller WE. 2009 Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30:1574-1586
23. Swerdlow RH, Burns JM, Khan SM. 2010 The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20(Suppl 2):S265-S279
24. Swerdlow RH, Khan SM. 2009 The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol 218:308-315
25. Swerdlow RH, Khan SM. 2004 A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 63:8-20
26. Lustbader JW, Cirilli M, Lin C, XuHW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, Wu H. 2004 ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 304:448-452
27. Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, Ankarcrona M. 2008 The amyloidβ-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 105:13145-13150
28. Pagani L, Eckert A. 2011 amyloid-β interaction with mitochondria. Int J Alzheimers Dis 2011:925050
29. Leuner K, Schutt T, Kurz C, Eckert SH, Schiller C, Occhipinti A, Mai S, Jendrach M, Eckert GP, Kruse SE, Palmiter RD, Brandt U, Drose S, Wittig I, Willem M, Haass C, Reichert AS, Mueller WE. 2012 Mitochondrion-derived reactive oxygen species lead to enhanced amyloid β formation. Antioxid Redox Signal 16:1421-1433
30. Rhein V, Song X, Wiesner A, Ittner LM, Baysang G, Meier F, Ozmen L, Bluethmann H, Dröse S, Brandt U, Savaskan E, Czech C, Götz J, Eckert A. 2009 amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 106:20057-20062
31. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F, Katayama T, Baldwin CT, Cheng R, Hasegawa H, Chen F, Shibata N, Lunetta KL, Pardossi-Piquard R, Bohm C, Wakutani Y, Cupples LA, Cuenco KT, Green RC, Pinessi L, Rainero I, Sorbi S, Bruni A, Duara R, Friedland RP, Inzelberg R, Hampe W, Bujo H, Song YQ, Andersen OM, Willnow TE, Graff-Radford N, Petersen RC, Dickson D, Der SD, Fraser PE, Schmitt-Ulms G, Younkin S, Mayeux R, Farrer LA, St George-Hyslop P. 2007 The neuronal sortilinrelated receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 39:168-177
32. Hernández F, de Barreda EG, Fuster-Matanzo A, Goñi-Oliver P, Lucas JJ, Avila J. 2009 The role of GSK3 in Alzheimer disease. Brain Res Bull 80:248-250
33. Kimura R, Kamino K, Yamamoto M, Nuripa A, Kida T, Kazui H, Hashimoto R, Tanaka T, Kudo T, Yamagata H, Tabara Y, Miki T, Akatsu H, Kosaka K, Funakoshi E, Nishitomi K, Sakaguchi G, Kato A, Hattori H, Uema T, Takeda M. 2007 The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease. Hum Mol Genet 16:15-23
34. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM. 2010 A TOMM40 variablelength polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 10:375-384
35. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, et al. 2009 Genome-wide association study identifies variants atCLUandCR1associated with Alzheimer's disease. Nat Genet 41:1094-1099
36. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, et al. 2009 Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41:1088-1093
37. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth Jr WT, Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, et al. 2010 Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 303:1832-1840
38. Kim J, Basak JM, Holtzman DM. 2009 The role of apolipoprotein E in Alzheimer's disease. Neuron 63:287-303
39. Karasinska JM, Hayden MR. 2011 Cholesterol metabolism in Huntington disease. Nat Rev Neurol 7:561-572
40. Dietschy JM, Turley SD. 2001 Cholesterol metabolism in the brain. Curr Opin Lipidol 12:105-112
41. Rebeck GW. 2004 Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. J Mol Neurosci 23:219-224
42. Hartmann T. 2001 Cholesterol, Aβ and Alzheimer's disease. Trends Neurosci 24:S45-S48
43. Shepardson NE, Shankar GM, Selkoe DJ. 2011 Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 68: 1239-1244
44. Shepardson NE, Shankar GM, Selkoe DJ. 2011 Cholesterol level and statin use in Alzheimer disease. II. Review of human trials and recommendations. Arch Neurol 68:1385-1392
45. Zelcer N, Tontonoz P. 2006 Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116:607-614
46. Adighibe O, Arepalli S, Duckworth J, Hardy J, Wavrant-De Vriéze F. 2006 Genetic variability at the LXR gene (NR1H2) may contribute to the risk of Alzheimer's disease. Neurobiol Aging 27:1431-1434
47. Zelcer N, Hong C, Boyadjian R, Tontonoz P. 2009 LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325:100-104
48. Koldamova RP, Lefterov IM, Staufenbiel M, Wolfe D, Huang S, Glorioso JC, Walter M, Roth MG, Lazo JS. 2005 The liverXreceptor ligand T0901317 decreases amyloidβ production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 280:4079-4088
49. Eikelenboom P, Veerhuis R, van Exel E, Hoozemans JJ, Rozemuller AJ, van Gool WA. 2011 The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8:142-150
50. Cao G, Bales KR, DeMattos RB, Paul SM. 2007 Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. Curr Alzheimer Res 4:179-184
51. Apfel R, Benbrook D, Lernhardt E, Ortiz MA, Salbert G, Pfahl M. 1994 A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol Cell Biol 14:7025-7035
52. Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. 1995 LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev 9:1033-1045
53. Janowski BA, Willy PJ, DeviTR, Falck JR, Mangelsdorf DJ. 1996 An oxysterol signalling pathway mediated by the nuclear receptor LXRβ. Nature 383:728-731
54. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG. 2001 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterolloaded cells. J Biol Chem 276:38378-38387
55. Jamroz-Wisniewska A, Wojcicka G, Horoszewicz K, Beltowski J. 2007 Liver X receptors (LXR). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy Hig Med Dosw (Online) 61:760-785
56. Bełtowski J, Semczuk A. 2010 Liver X receptor (LXR) and the reproductive system: a potential novel target for therapeutic intervention. Pharmacol Rep 62:15-27
57. Gerin I, DolinskyVW, Shackman JG, Kennedy RT, Chiang SH, Burant CF, Steffensen KR, Gustafsson JA, MacDougald OA. 2005 LXRβ is required for adipocyte growth, glucose homeostasis, and β cell function. J Biol Chem 280: 23024-23031
58. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ. 2001 Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-1870
59. Willy PJ, Mangelsdorf DJ. 1997 Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. Genes Dev 11:289-298
60. Chen JD, Evans RM. 1995 A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature 377: 454-457
61. Hörlein AJ, Näär AM, Heinzel T, Torchia J, Gloss B, Kurokawa R, Ryan A, Kamei Y, Söderström M, Glass CK. 1995 Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature 377:397-404
62. Ghisletti S, Huang W, Ogawa S, Pascual G, Lin ME, Willson TM, Rosenfeld MG, Glass CK. 2007 Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXR and PPARβ.Mol Cell 25:57-70
63. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. 2003 Reciprocal regulation of inflammation and lipid metabolism by liverXreceptors. Nat Med 9:213-219
64. Tall AR, Costet P, Wang N. 2002 Regulation and mechanisms of macrophage cholesterol efflux. J Clin Invest 110: 899-904
65. Wang Y, Rogers PM, Su C, Varga G, Stayrook KR, Burris. TP 2008 Regulation of cholesterologenesis by the oxysterol receptor, LXRβ. J Biol Chem 283:26332-26339
66. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, ShimomuraI, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. 2000 Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRβ and LXRβ. Genes Dev 14:2819-2830
67. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, Lustig KD, Shan B. 2000 Role of LXR in control of lipogenesis. Genes Dev 14:2831-2838
68. Qin Y, Dalen KT, Gustafsson JA, Nebb HI. 2009 Regulation of hepatic fatty acid elongase 5 by LXRβ-SREBP-1c. Biochim Biophys Acta 1791:140-147
69. Tontonoz P, Mangelsdorf DJ. 2003 Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17:985-993
70. Baranowski M. 2008 Biological role of liver X receptors. J Physiol Pharmacol 59(Suppl 7):31-55
71. Peet DJ, Turley SD, Ma W, Janowski BA, Lobaccaro JM, Hammer RE, Mangelsdorf DJ. 1998 Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR β. Cell 93:693-704
72. Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, Rudling M, Angelin B, Björkhem I, Pettersson S, Gustafsson JA. 2001 Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J Clin Invest 107:565-573
73. Chiang JY, Kimmel R, Stroup D. 2001 Regulation of cholesterol 7β-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRβ). Gene 262:257-265
74. Li T, Owsley E, Matozel M, Hsu P, Novak CM, Chiang JY. 2010 Transgenic expression of cholesterol 7β-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 52:678-690
75. Li T, Matozel M, Boehme S, Kong B, Nilsson LM, Guo G, Ellis E, Chiang JY. 2011 Overexpression of cholesterol 7β-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 53:996-1006
76. Castrillo A, Tontonoz P. 2004 Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 20:455-480
77. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, Wang X, Lusis AJ, Tontonoz P, Schulman IG. 2002 Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA 99:11896-11901
78. Calkin AC, Tontonoz P. 2010 Liver x receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 30:1513-1518
79. Wang N, Lan D, Chen W, Matsuura F, Tall AR. 2004 ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101:9774-9779
80. Hozoji M, Munehira Y, Ikeda Y, Makishima M, Matsuo M, Kioka N, Ueda K. 2008 Direct interaction of nuclear liver X receptor-β with ABCA1 modulates cholesterol efflux. J Biol Chem 283:30057-30063
81. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P. 2001 A PPAR β-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171
82. Repa JJ, Berge KE, Pomajzl C, Richardson JA, Hobbs H, Mangelsdorf DJ. 2002 Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors β and β. J Biol Chem 277:18793-18800
83. Lee MH, Lu K, Patel SB. 2001 Genetic basis of sitosterolemia. Curr Opin Lipidol 12:141-149
84. Horton JD, Shah NA, Warrington JA, Anderson NN, Park SW, Brown MS, Goldstein JL. 2003 Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 100:12027-12032
85. Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Sato R, Kimura S, Ishibashi S, Yamada N. 2002 Transcriptional activities of nuclear SREBP-1a,-1c, and-2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 43: 1220-1235
86. Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks VW, Bakker AH, Ramaekers FC, de Vente J, Groen AK, Wellington CL, Kuipers F, Mulder M. 2006 24(S)-Hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem 281:12799-12808
87. Sato K, Kamada T. 2011 Regulation of bile acid, cholesterol, and fatty acid synthesis in chicken primary hepatocytes by different concentrations of T0901317, an agonist of liver X receptors. Comp Biochem Physiol A Mol Integr Physiol 158:201-206
88. Curtiss LK, Boisvert WA. 2000 Apolipoprotein E and atherosclerosis. Curr Opin Lipidol 11:243-251
89. Rensen PC, Jong MC, van Vark LC, van der Boom H, Hendriks WL, van Berkel TJ, Biessen EA, Havekes LM. 2000 Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem 275:8564-8571
90. Elshourbagy NA, Liao WS, Mahley RW, Taylor JM. 1985 Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc Natl Acad Sci USA 82:203-207
91. Mahley RW. 1988 Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-630
92. Kockx M, Jessup W, Kritharides L. 2008 Regulation of endogenous apolipoprotein E secretion by macrophages. Arterioscler Thromb Vasc Biol 28:1060-1067
93. Zhong N, Weisgraber KH. 2009 Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J Biol Chem 284:6027-6031
94. Patel AB, Khumsupan P, Narayanaswami V. 2010 Pyrene fluorescence analysis offers new insights into the conformation of the lipoprotein-binding domain of human apolipoprotein E. Biochemistry 49:1766-1775
95. Wilson C, Wardell MR, Weisgraber KH, Mahley RW, Agard DA. 1991 Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 252:1817-1822
96. Cun W, Jiang J, Luo G. 2010 The C-terminal β-helix domain of apolipoprotein E is required for interaction with nonstructural protein5Aand assembly of hepatitisCvirus. J Virol 84:11532-11541
97. Zannis VI, Just PW, Breslow JL. 1981 Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet 33:11-24
98. Olaisen B, Teisberg P, Gedde-Dahl Jr T. 1982 The locus for apolipoprotein E (apoE) is linked to the complement component C3 (C3) locus on chromosome 19 in man. Hum Genet 62:233-236
99. Hatters DM, Peters-Libeu CA, Weisgraber KH. 2006 Apolipoprotein E structure: insights into function. Trends Biochem Sci 31:445-454
100. Zhong N, Ramaswamy G, Weisgraber KH. 2009 Apolipoprotein E4 domain interaction induces endoplasmic reticulum stress and impairs astrocyte function. J Biol Chem 284:27273-27280
101. Strittmatter WJ, Roses AD. 1995 Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci USA 92:4725-4727
102. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. 1992 Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468-471
103. Plump AS, Smith JD, Hayek T, Aalto-SetäläK, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. 1992 Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353
104. Plump AS, Breslow JL. 1995 Apolipoprotein E and the apolipoprotein E-deficient mouse. Annu Rev Nutr 15:495-518
105. Williams DL, Dawson PA, Newman TC, Rudel LL. 1985 Apolipoprotein E synthesis in peripheral tissues of nonhuman primates. J Biol Chem 260:2444-2451
106. Newman TC, Dawson PA, Rudel LL, Williams DL. 1985 Quantitation of apolipoprotein E mRNA in the liver and peripheral tissues of nonhuman primates. J BiolChem260: 2452-2457
107. Zechner R, Moser R, Newman TC, Fried SK, Breslow JL. 1991 Apolipoprotein E gene expression in mouse 3T3-L1 adipocytes and human adipose tissue and its regulation by differentiation and lipid content. J Biol Chem 266:10583-10588
108. Huang ZH, Espiritu DJ, Uy A, Holterman AX, Vitello J, Mazzone T. 2011 Adipose tissue depot-specific differences in adipocyte apolipoprotein E expression. Metabolism 60: 1692-1701
109. Shih SJ, Allan C, Grehan S, Tse E, Moran C, Taylor JM. 2000 Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue. J Biol Chem 275:31567-31572
110. Basheeruddin K, Stein P, Strickland S, Williams DL. 1987 Expression of the murine apolipoprotein E gene is coupled to the differentiated state of F9 embryonal carcinoma cells. Proc Natl Acad Sci USA 84:709-713
111. Staels B, Auwerx J, Chan L, van Tol A, Rosseneu M, Verhoeven G. 1989 Influence of development, estrogens, and food intake on apolipoprotein A-I, A-II, and E mRNA in rat liver and intestine. J Lipid Res 30:1137-1145
112. Zuckerman SH, Evans GF, O'Neal L. 1992 Cytokine regulation of macrophage apo E secretion: opposing effects of GM-CSF and TGF-β. Atherosclerosis 96:203-214
113. Singh NN, Ramji DP. 2006 Transforming growth factor-β-induced expression of the apolipoproteinEgene requires c-Jun N-terminal kinase, p38 kinase, and casein kinase 2. Arterioscler Thromb Vasc Biol 26:1323-1329
114. Gafencu AV, Robciuc MR, Fuior E, Zannis VI, Kardassis D, Simionescu M. 2007 Inflammatory signaling pathways regulating ApoE gene expression in macrophages. J Biol Chem 282:21776-21785
115. Galetto R, Albajar M, Polanco JI, Zakin MM, Rodríguez-Rey JC. 2001 Identification of a peroxisome-proliferatoractivated-receptor response element in the apolipoprotein E gene control region. Biochem J 357:521-527
116. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P. 2001 LXR control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 98:507-512
117. Huwait EA, Greenow KR, Singh NN, Ramji DP. 2011 A novel role for c-Jun N-terminal kinase and phosphoinositide 3-kinase in the liver X receptor-mediated induction of macrophage gene expression. Cell Signal 23:542-549
118. Yue L, Christman JW, Mazzone T. 2008 Tumor necrosis factor-β-mediated suppression of adipocyte apolipoprotein E gene transcription: primary role for the nuclear factor (NF)-βB pathway and NFβB p50. Endocrinology 149: 4051-4058
119. Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T. 2004 Divergent effects of peroxisome proliferator-activated receptor β agonists and tumor necrosis factor β on adipocyte ApoE expression. J Biol Chem 279:47626-47632
120. Huang ZH, Reardon CA, Mazzone T. 2006 Endogenous ApoE expression modulates adipocyte triglyceride content and turnover. Diabetes 55:3394-3402
121. Yue L, Mazzone T. 2009 Peroxisome proliferator-activated receptor β stimulation of adipocyte ApoE gene transcription mediated by the liver receptorXpathway. J Biol Chem 284:10453-10461
122. Shibata N, Glass CK. 2010 Macrophages, oxysterols and atherosclerosis. Circ J 74:2045-2051
123. Jiang XC, Beyer TP, Li Z, Liu J, Quan W, Schmidt RJ, Zhang Y, Bensch WR, Eacho PI, Cao G. 2003 Enlargement of high density lipoprotein in mice via liver X receptor activation requires apolipoprotein E and is abolished by cholesteryl ester transfer protein expression. J Biol Chem 278:49072-49078
124. Ducheix S, Lobaccaro JM, Martin PG, Guillou H. 2011 Liver X Receptor: an oxysterol sensor and a major player in the control of lipogenesis. Chem Phys Lipids 164:500-514
125. Brown MS, Goldstein JL. 1997 The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89:331-340
126. Edwards PA, Tabor D, Kast HR, Venkateswaran A. 2000 Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta 1529:103-113
127. Yokoyama C, Wang X, Briggs MR, Admon A, Wu J, Hua X, Goldstein JL, Brown MS. 1993 SREBP-1, a basic-helixloop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75: 187-197
128. Horton JD, Bashmakov Y, Shimomura I, Shimano H. 1998 Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA 95:5987-5992
129. Shimano H, Yahagi N, Amemiya-Kudo M, Hasty AH, Osuga J, Tamura Y, Shionoiri F, Iizuka Y, Ohashi K, Harada K, Gotoda T, Ishibashi S, Yamada N. 1999 Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J Biol Chem 274:35832-35839
130. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. 1998 Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest 101: 2331-2339
131. Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL. 1996 Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. J Clin Invest 98:1575-1584
132. Shimano H, Horton JD, Shimomura I, Hammer RE, Brown MS, Goldstein JL. 1997 Isoform 1c of sterol regulatory element binding protein is less active than isoform 1a in livers of transgenic mice and in cultured cells. J Clin Invest 99:846-854
133. Kim JB, Sarraf P, Wright M, Yao KM, Mueller E, Solanes G, Lowell BB, Spiegelman BM. 1998 Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 101:1-9
134. Bobard A, Hainault I, Ferré P, Foufelle F, Bossard P. 2005 Differential regulation of sterol regulatory element-binding protein 1c transcriptional activity by insulin and liver X receptor during liver development. J Biol Chem 280: 199-206
135. Zhang Y, Repa JJ, Gauthier K, Mangelsdorf DJ. 2001 Regulation of lipoprotein lipase by the oxysterol receptors, LXRβ and LXRβ. J Biol Chem 276:43018-43024
136. Talukdar S, Hillgartner FB. 2006 The mechanism mediating the activation of acetyl-coenzyme A carboxylase-β gene transcription by the liver X receptor agonist T0-901317. J Lipid Res 47:2451-2461
137. Joseph SB, Laffitte BA, Patel PH, Watson MA, Matsukuma KE, Walczak R, Collins JL, Osborne TF, Tontonoz P. 2002 Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J Biol Chem 277:11019-11025
138. Chu K, Miyazaki M, Man WC, Ntambi JM. 2006 Stearoylcoenzyme A desaturase 1 deficiency protects against hypertriglyceridemia and increases plasma high-density lipoprotein cholesterol induced by liver X receptor activation. Mol Cell Biol 26:6786-6798
139. Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K, Beltowski J. 2007 Liver X receptors (LXR). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online) 61:736-759
140. Cha JY, Repa JJ. 2007 The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response elementbinding protein is a target gene of LXR. J Biol Chem 282: 743-751
141. Lund EG, Peterson LB, Adams AD, Lam MH, Burton CA, Chin J, Guo Q, Huang S, Latham M, Lopez JC, Menke JG, Milot DP, Mitnaul LJ, Rex-Rabe SE, Rosa RL, Tian JY, Wright SD, Sparrow CP. 2006 Different roles of liver X receptor β and β in lipid metabolism: effects of an β-selective and a dual agonist in mice deficient in each subtype. Biochem Pharmacol 71:453-463
142. Steffensen KR, Nilsson M, Schuster GU, Stulnig TM, Dahlman-Wright K, Gustafsson JA. 2003 Gene expression profiling in adipose tissue indicates different transcriptional mechanisms of liver X receptors β and β, respectively. Biochem Biophys Res Commun 310:589-593
143. Hessvik NP, Boekschoten MV, Baltzersen MA, Kersten S, Xu X, Andersén H, Rustan AC, Thoresen GH. 2010 LXRβ is the dominant LXR subtype in skeletal muscle regulating lipogenesis and cholesterol efflux. Am J Physiol Endocrinol Metab 298:E602-E613
144. Laffitte BA, Chao LC, Li J, Walczak R, Hummasti S, Joseph SB, Castrillo A, Wilpitz DC, Mangelsdorf DJ, Collins JL, Saez E, Tontonoz P. 2003 Activation of liverXreceptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci USA 100:5419-5424
145. Liu Y, Yan C, Wang Y, Nakagawa Y, Nerio N, Anghel A, Lutfy K, Friedman TC. 2006 Liver X receptor agonist T0901317 inhibition of glucocorticoid receptor expression in hepatocytes may contribute to the amelioration of diabetic syndrome in db/db mice. Endocrinology 147: 5061-5068
146. Efanov AM, Sewing S, Bokvist K, Gromada J. 2004 Liver Xreceptor activation stimulates insulin secretion via modulation of glucose and lipid metabolism in pancreatic β-cells. Diabetes 53(Suppl 3):S75-S78
147. Zitzer H, Wente W, Brenner MB, Sewing S, Buschard K, Gromada J, Efanov AM. 2006 Sterol regulatory elementbinding protein 1 mediates liver X receptor-β-induced increases in insulin secretion and insulin messenger ribonucleic acid levels. Endocrinology 147:3898-3905
148. Ketterer C, Mussig K, Machicao F, Stefan N, Fritsche A, Haring HU, Staiger H. 2011 Genetic variation within the NR1H2 gene encoding liver X receptor β associates with insulin secretion in subjects at increased risk for type 2 diabetes. J Mol Med (Berl) 89:75-81
149. Mitro N, Mak PA, Vargas L, Godio C, Hampton E, Molteni V, Kreusch A, Saez E. 2007 The nuclear receptor LXR is a glucose sensor. Nature 445:219-223
150. Denechaud PD, Bossard P, Lobaccaro JM, Millatt L, Staels B, Girard J, Postic C. 2008 ChREBP, but not LXR, is required for the induction of glucose-regulated genes in mouse liver. J Clin Invest 118:956-964
151. Brankatschk M, Eaton S. 2010 Lipoprotein particles cross the blood-brain barrier in Drosophila. J Neurosci 30: 10441-10447
152. Turley SD, Burns DK, Dietschy JM. 1998 Preferential utilization of newly synthesized cholesterol for brain growth in neonatal lambs. Am J Physiol 274:E1099-E1105
153. Björkhem I, Lütjohann D, Diczfalusy U, Ståhle L, Ahlborg G, Wahren J. 1998 Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39:1594-1600
154. Jurevics H, Morell P. 1995 Cholesterol for synthesis of myelin is made locally, not imported into brain. J Neurochem 64:895-901
155. Dietschy JM. 2009 Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem 390:287-293
156. Morell P, Jurevics H. 1996 Origin of cholesterol in myelin. Neurochem Res 21:463-470
157. Nieweg K, Schaller H, Pfrieger FW. 2009 Marked differences in cholesterol synthesis between neurons and glial cells from postnatal rats. J Neurochem 109:125-134
158. Dietschy JM, Turley SD. 2004 Thematic review series: brain Lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 45:1375-1397
159. Hayashi H, Campenot RB, Vance DE, Vance JE. 2004 Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J Biol Chem 279: 14009-14015
160. Mauch DH, Nägler K, Schumacher S, Göritz C, Müller EC, Otto A, Pfrieger FW. 2001 CNS synaptogenesis promoted by glia-derived cholesterol. Science 294:1354-1357
161. Thelen KM, Falkai P, Bayer TA, Lütjohann D. 2006 Cholesterol synthesis rate inhumanhippocampus declines with aging. Neurosci Lett 403:15-19
162. Pfrieger FW, Ungerer N. 2011 Cholesterol metabolism in neurons and astrocytes. Prog Lipid Res 50:357-371
163. -/-, and human apoE transgenic mice. J Biol Chem 274:30001-30007
164. Oram JF, Heinecke JW. 2005 ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85:1343-1372
165. Kim WS, Weickert CS, Garner B. 2008 Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem 104:1145-1166
166. Vaughan AM, Oram JF. 2006 ABCA1 and ABCG1 or ABCG4 act sequentially to remove cellular cholesterol and generate cholesterol-rich HDL. J Lipid Res 47:2433-2443
167. FukumotoH, DengA, Irizarry MC, Fitzgerald ML, Rebeck GW. 2002 Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Aβ levels. J Biol Chem 277:48508-48513
168. Hirsch-Reinshagen V, Zhou S, Burgess BL, Bernier L, McIsaac SA, Chan JY, Tansley GH, Cohn JS, Hayden MR, Wellington CL. 2004 Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J Biol Chem 279:41197-41207
169. Wahrle SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T, Holtzman DM. 2004 ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J Biol Chem 279:40987-40993
170. Bojanic DD, Tarr PT, Gale GD, Smith DJ, Bok D, Chen B, Nusinowitz S, Lövgren-Sandblom A, Björkhem I, Edwards PA. 2010 Differential expression and function of ABCG1 and ABCG4 during development and aging. J Lipid Res 51:169-181
171. Wang N, Yvan-Charvet L, Lütjohann D, Mulder M, Vanmierlo T, Kim TW, Tall AR. 2008 ATP-binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux toHDLand regulate sterol accumulation in the brain. FASEB J 22:1073-1082
172. Tarr PT, Edwards PA. 2008 ABCG1 and ABCG4 are coexpressed in neurons and astrocytes of the CNS and regulate cholesterol homeostasis through SREBP-2. J Lipid Res 49:169-182
173. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH. 1987 Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J Biol Chem 262:14352-14360
174. Swanson LW, Simmons DM, Hofmann SL, Goldstein JL, Brown MS. 1988 Localization of mRNA for low density lipoprotein receptor and a cholesterol synthetic enzyme in rabbit nervous system by in situ hybridization. Proc Natl Acad Sci USA 85:9821-9825
175. Wolf BB, Lopes MB, VandenBerg SR, Gonias SL. 1992 Characterization and immunohistochemical localization ofβ 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol 141: 37-42
176. Bu G, Maksymovitch EA, Geuze H, Schwartz AL. 1994 Subcellular localization and endocytic function of low density lipoprotein receptor-related protein inhumanglioblastoma cells. J Biol Chem 269:29874-29882
177. Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM, Holtzman DM. 2009 Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance. Neuron 64:632-644
178. Carstea ED, Morris JA, Coleman KG, Loftus SK, Zhang D, Cummings C, Gu J, Rosenfeld MA, Pavan WJ, Krizman DB, Nagle J, Polymeropoulos MH, Sturley SL, Ioannou YA, Higgins ME, Comly M, Cooney A, Brown A, Kaneski CR, Blanchette-Mackie EJ, Dwyer NK, Neufeld EB, Chang TY, Liscum L, Strauss III JF, et al. 1997 Niemann-PickC1disease gene: homology to mediators of cholesterol homeostasis. Science 277:228-231
179. Loftus SK, Morris JA, Carstea ED, Gu JZ, Cummings C, Brown A, Ellison J, Ohno K, Rosenfeld MA, Tagle DA, Pentchev PG, Pavan WJ. 1997 Murine model of Niemann-PickCdisease: mutation in a cholesterol homeostasis gene. Science 277:232-235
180. Kwon HJ, Abi-Mosleh L, Wang ML, Deisenhofer J, Goldstein JL, Brown MS, Infante RE. 2009Structure of N-terminal domain ofNPC1reveals distinct subdomains for binding and transfer of cholesterol. Cell 137:1213-1224
181. Naureckiene S, Sleat DE, Lackland H, Fensom A, Vanier MT, Wattiaux R, Jadot M, Lobel P. 2000 Identification of HE1as the second gene of Niemann-PickCdisease. Science 290:2298-2301
182. German DC, Liang CL, Song T, Yazdani U, Xie C, Dietschy JM. 2002 Neurodegeneration in the Niemann-Pick C mouse: glial involvement. Neuroscience 109:437-450
183. Walkley SU, Suzuki K. 2004 Consequences of NPC1 and NPC2 loss of function in mammalian neurons. Biochim Biophys Acta 1685:48-62
184. Zervas M, Dobrenis K, Walkley SU. 2001 Neurons in Niemann-Pick disease typeCaccumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol 60:49-64
185. Reid PC, Sakashita N, Sugii S, Ohno-Iwashita Y, Shimada Y, HickeyWF, Chang TY. 2004Anovel cholesterol stain reveals earlyneuronalcholesterolaccumulationin theNiemann-Pick type C1 mouse brain. J Lipid Res 45:582-591
186. Wollmer MA. 2010 Cholesterol-related genes in Alzheimer's disease. Biochim Biophys Acta 1801:762-773
187. Vance JE, Hayashi H, Karten B. 2005 Cholesterol homeostasis in neurons and glial cells. Semin Cell Dev Biol 16: 193-212
188. Karten B, Peake KB, Vance JE. 2009 Mechanisms and consequences of impaired lipid trafficking in Niemann-Pick type C1-deficient mammalian cells. Biochim Biophys Acta 1791:659-670
189. Burke KT, Colvin PL, Myatt L, Graf GA, Schroeder F, Woollett LA. 2009 Transport of maternal cholesterol to the fetus is affected by maternal plasma cholesterol concentrations in the golden Syrian hamster. J Lipid Res 50:1146-1155
190. Porter FD, Herman GE. 2011 Malformation syndromes caused by disorders of cholesterol synthesis. J Lipid Res 52:6-34
191. Olofsson SO, Boström P, Andersson L, Rutberg M, Perman J, Borén J. 2009 Lipid droplets as dynamic organelles connecting storage and efflux of lipids. Biochim Biophys Acta 1791:448-458
192. Koldamova RP, Lefterov IM, Ikonomovic MD, Skoko J, Lefterov PI, Isanski BA, DeKosky ST, Lazo JS. 2003 22 R-hydroxycholesterol and 9-cis-retinoic acid induce ATPbinding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloidβ secretion. J Biol Chem 278:13244-13256
193. Minagawa H, Gong JS, Jung CG, Watanabe A, Lund-Katz S, Phillips MC, Saito H, Michikawa M. 2009 Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. J Neurosci Res 87:2498-2508
194. Russell DW. 2000 Oxysterol biosynthetic enzymes. Biochim Biophys Acta 1529:126-135
195. Björkhem I, Lütjohann D, Breuer O, Sakinis A, Wennmalm A. 1997 Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J Biol Chem 272:30178-30184
196. Lund EG, Guileyardo JM, Russell DW. 1999 cDNAcloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96: 7238-7243
197. Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Sidén A, Diczfalusy U, Björkhem I. 1996 Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24Shydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 93:9799-9804
198. Leoni V, Caccia C. 2011 Oxysterols as biomarkers in neurodegenerative diseases. Chem Phys Lipids 164:515-524
199. Pfrieger FW. 2003 Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? Bioessays 25:72-78
200. Hudry E, Van Dam D, Kulik W, De Deyn PP, Stet FS, Ahouansou O, Benraiss A, Delacourte A, Bougne'res P, Aubourg P, Cartier N. 2010 Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther 18:44-53
201. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW. 2006 Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 103:3869-3874
202. Leoni V, Masterman T, Patel P, Meaney S, Diczfalusy U, Björkhem I. 2003 Side chain oxidized oxysterols in cerebrospinal fluid and the integrity of blood-brain and bloodcerebrospinal fluid barriers. J Lipid Res 44:793-799
203. Båvner A, Shafaati M, Hansson M, Olin M, Shpitzen S, Meiner V, Leitersdorf E, Björkhem I. 2010 On the mechanism of accumulation of cholestanol in the brain of mice with a disruption of sterol 27-hydroxylase. J Lipid Res 51:2722-2730
204. Burnett JR, Moses EA, Croft KD, Brown AJ, Grainger K, Vasikaran SD, Leitersdorf E, Watts GF. 2001 Clinical and biochemical features, molecular diagnosis and long-term management of a case of cerebrotendinous xanthomatosis. Clin Chim Acta 306:63-69
205. Brown 3rd J, Theisler C, Silberman S, Magnuson D, Gottardi-Littell N, Lee JM, Yager D, Crowley J, Sambamurti K, Rahman MM, Reiss AB, Eckman CB, Wolozin B. 2004 Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 279:34674-34681
206. Gilardi F, Viviani B, Galmozzi A, Boraso M, Bartesaghi S, Torri A, Caruso D, Crestani M, Marinovich M, de Fabiani E. 2009 Expression of sterol 27-hydroxylase in glial cells and its regulation by liver X receptor signaling. Neuroscience 164:530-540
207. Heverin M, Bogdanovic N, Lütjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Björkhem I. 2004 Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res 45:186-193
208. Lund EG, Kerr TA, Sakai J, Li WP, Russell DW. 1998 cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. J Biol Chem 273:34316-34327
209. Papassotiropoulos A, Lambert JC, Wavrant-De Vriéze F, Wollmer MA, von der Kammer H, Streffer JR, Maddalena A, Huynh KD, Wolleb S, Lutjohann D, Schneider B, Thal DR, Grimaldi LM, Tsolaki M, Kapaki E, Ravid R, Konietzko U, Hegi T, Pasch T, Jung H, Braak H, Amouyel P, Rogaev EI, Hardy J, Hock C, Nitsch RM. 2005 Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neurodegener Dis 2:233-241
210. Zhao C, Dahlman-Wright K. 2010 LiverXreceptor in cholesterol metabolism. J Endocrinol 204:233-240
211. Andersson S, Gustafsson N, Warner M, Gustafsson JA. 2005 Inactivation of liverXreceptorβ leads to adult-onset motor neuron degeneration in male mice. Proc Natl Acad Sci USA 102:3857-3862
212. Whitney KD, Watson MA, Collins JL, Benson WG, Stone TM, Numerick MJ, Tippin TK, Wilson JG, Winegar DA, Kliewer SA. 2002 Regulation of cholesterol homeostasis by the liver X receptors in the central nervous system. Mol Endocrinol 16:1378-1385
213. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. 2002 Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA 99:13878-13883
214. Repa JJ, Li H, Frank-Cannon TC, Valasek MA, Turley SD, Tansey MG, Dietschy JM. 2007 LiverXreceptor activation enhances cholesterol loss from the brain, decreases neuroinflammation, and increases survival of the NPC1 mouse. J Neurosci 27:14470-14480
215. Liang Y, Lin S, Beyer TP, Zhang Y, Wu X, Bales KR, DeMattos RB, May PC, Li SD, Jiang XC, Eacho PI, Cao G, Paul SM. 2004 A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem 88:623-634
216. Masliah E, MalloryM, Ge N, AlfordM, Veinbergs I, Roses AD. 1995 Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol 136:107-122
217. Gordon I, Genis I, Grauer E, Sehayek E, Michaelson DM. 1996 Biochemical and cognitive studies of apolipoprotein-E-deficient mice. Mol Chem Neuropathol 28:97-103
218. Masliah E, Samuel W, Veinbergs I, Mallory M, Mante M, Saitoh T. 1997 Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res 751:307-314
219. Oitzl MS, Mulder M, Lucassen PJ, Havekes LM, Grootendorst J, de Kloet ER. 1997 Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. Brain Res 752:189-196
220. Koldamova R, Staufenbiel M, Lefterov I. 2005 Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J Biol Chem 280:43224-43235
221. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, TippinTK, WangX, Lusis AJ, HsuehWA, LawRE, Collins JL, Willson TM, Tontonoz P. 2002 Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 99:7604-7609
222. Im SS, Osborne TF. 2011 Liver x receptors in atherosclerosis and inflammation. Circ Res 108:996-1001
223. Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P. 2003 Crosstalk between LXRand toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol Cell 12: 805-816
224. Fowler AJ, Sheu MY, Schmuth M, Kao J, Fluhr JW, Rhein L, Collins JL, Willson TM, Mangelsdorf DJ, Elias PM, Feingold KR. 2003 LiverXreceptor activators display antiinflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J Invest Dermatol 120:246-255
225. Joseph SB, Bradley MN, Castrillo A, Bruhn KW, Mak PA, Pei L, Hogenesch J, O'connellRM, Cheng G, Saez E, Miller JF, Tontonoz P. 2004 LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119:299-309
226. Valledor AF, Hsu LC, Ogawa S, Sawka-Verhelle D, Karin M, Glass CK. 2004 Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc Natl Acad Sci USA 101:17813-17818
227. Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A, Subramaniam S, David M, Rosenfeld MG, Glass CK. 2005 Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122:707-721
228. Zhang-Gandhi CX, Drew PD. 2007 Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes. J Neuroimmunol 183: 50-59
229. Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, HausnerMA, Shih R, Parks JS, Edwards PA, Jamieson BD, Tontonoz P. 2008 LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134:97-111
230. A-Gonzalez N, Bensinger SJ, Hong C, Beceiro S, Bradley MN, Zelcer N, Deniz J, Ramirez C, Díaz M, Gallardo G, de Galarreta CR, Salazar J, Lopez F, Edwards P, Parks J, Andujar M, Tontonoz P, Castrillo A. 2009 Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 31:245-258
231. HongC, Walczak R, DhamkoH, BradleyMN, Marathe C, Boyadjian R, Salazar JV, Tontonoz P. 2011 Constitutive activation ofLXRin macrophages regulates metabolic and inflammatory gene expression: identification of ARL7 as a direct target. J Lipid Res 52:531-539
232. Bensinger SJ, Tontonoz P. 2008 Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 454:470-477
233. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, Rose DW, Willson TM, Rosenfeld MG, Glass CK. 2005 A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-β. Nature 437:759-763
234. Morales JR, Ballesteros I, Deniz JM, Hurtado O, Vivancos J, Nombela F, Lizasoain I, Castrillo A, Moro MA. 2008 Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation 118:1450-1459
235. Pascual-García M, Carbó JM, León T, Matalonga J, Out R, Van Berkel T, Sarrias MR, Lozano F, Celada A, Valledor AF. 2011 Liver X receptors inhibit macrophage proliferation through down-regulation of cyclins D1 and B1 and cyclin-dependent kinases 2 and 4. J Immunol 186:4656-4667
236. Cui G, Qin X, Wu L, Zhang Y, Sheng X, Yu Q, Sheng H, Xi B, Zhang JZ, Zang YQ. 2011 Liver X receptor (LXR) mediates negative regulation of mouse and human Th17 differentiation. J Clin Invest 121:658-670
237. Di Paolo G, Kim TW. 2011 Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 12: 284-296
238. Matsuzaki T, Sasaki K, Hata J, Hirakawa Y, Fujimi K, Ninomiya T, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T. 2011 Association of Alzheimer disease pathology with abnormal lipid metabolism: The Hisayama Study. Neurology 77:1068-1075
239. Schönknecht P, Lütjohann D, Pantel J, Bardenheuer H, Hartmann T, von Bergmann K, Beyreuther K, Schröder J. 2002 Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls. Neurosci Lett 324:83-85
240. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. 2001 Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 98:5856-5861
241. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. 2000 Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57:1439-1443
242. Sparks DL. 2011 Alzheimer disease: statins in the treatment of Alzheimer disease. Nat Rev Neurol 7:662-663
243. Kurata T, Miyazaki K, Kozuki M, Panin VL, Morimoto N, Ohta Y, Nagai M, Ikeda Y, Matsuura T, Abe K. 2011 Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice. Brain Res 1371:161-170
244. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. 2011 A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77:556-563
245. Butterfield DA, Barone E, Mancuso C. 2011 Cholesterolindependent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res 64:180-186
246. Wolozin B. 2001 A fluid connection: cholesterol and Aβ. Proc Natl Acad Sci USA 98:5371-5373
247. Bogdanovic N, Bretillon L, Lund EG, Diczfalusy U, Lannfelt L, Winblad B, Russell DW, Björkhem I. 2001 On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci Lett 314:45-48
248. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, SeidahNG, OddoS, LaFerla FM, Spencer TA, Hickey WF, Chang TY. 2010 ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci USA 107:3081-3086
249. Halford RW, Russell DW. 2009 Reduction of cholesterol synthesis in the mouse brain does not affect amyloid formation in Alzheimer's disease, but does extend lifespan. Proc Natl Acad Sci USA 106:3502-3506
250. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, Russell DW. 2003 Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278:22980-22988
251. Xie C, Lund EG, Turley SD, Russell DW, Dietschy JM. 2003 Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res 44:1780-1789
252. Howland DS, Trusko SP, Savage MJ, Reaume AG, Lang DM, Hirsch JD, Maeda N, Siman R, Greenberg BD, Scott RW, Flood DG. 1998 Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol. J Biol Chem 273:16576-16582
253. Mizuno T, Nakata M, Naiki H, Michikawa M, Wang R, Haass C, Yanagisawa K. 1999 Cholesterol-dependent generation of a seeding amyloidβ-protein in cell culture. J Biol Chem 274:15110-15114
254. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. 1998 Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 95:6460-6464
255. Glöckner F, Meske V, Lütjohann D, Ohm TG. 2011 Dietary cholesterol and its effect on tau protein: a study in apolipoprotein E-deficient and P301L human tau mice. J Neuropathol Exp Neurol 70:292-301
256. Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. 2008 Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest 118:671-682
257. Wollmer MA, Streffer JR, Lütjohann D, Tsolaki M, Iakovidou V, Hegi T, Pasch T, Jung HH, Bergmann K, Nitsch RM, Hock C, Papassotiropoulos A. 2003 ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol Aging 24:421-426
258. Uehara Y, Yamada T, Baba Y, Miura S, Abe S, Kitajima K, Higuchi MA, Iwamoto T, Saku K. 2008 ATP-binding cas-sette transporter G4 is highly expressed in microglia in Alzheimer's brain. Brain Res 1217:239-246
259. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993 Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90:1977-1981
260. DeMattos RB. 2004 Apolipoprotein E dose-dependent modulation ofβ-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J Mol Neurosci 23:255-262
261. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM. 2004 Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides. Nat Med 10:719-726
262. Zhao L, Lin S, Bales KR, Gelfanova V, Koger D, Delong C, Hale J, Liu F, Hunter JM, Paul SM. 2009 Macrophagemediated degradation of β-amyloid via an apolipoprotein E isoform-dependent mechanism. J Neurosci 29:3603-3612
263. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, WillsonTM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. 2008 ApoE promotes the proteolytic degradation of Aβ. Neuron 58:681-693
264. Bales KR, Verina T, Dodel RC, DuY, Altstiel L, BenderM, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM. 1997 Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat Genet 17:263-264
265. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLongCA, Piccardo P, Petegnief V, Ghetti B, Paul SM. 1999 Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 96:15233-15238
266. Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizarry MC, Hyman BT. 2000 Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47:739-747
267. Kim J, Jiang H, Park S, Eltorai AE, Stewart FR, Yoon H, Basak JM, Finn MB, Holtzman DM. 2011 Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci 31: 18007-18012
268. Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM. 2005 Deletion of Abca1 increases Aβ deposition in the PDAPP transgenic mouse model of Alzheimer disease. J Biol Chem 280:43236-43242
269. Nishitsuji K, Hosono T, Nakamura T, Bu G, Michikawa M. 2011 Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model. J Biol Chem 286:17536-17542
270. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. 2006 Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5:64-74
271. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. 2004 Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474-481
272. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM. 1999 Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53:1937-1942
273. Cukierman T, Gerstein HC, Williamson JD. 2005 Cognitive decline and dementia in diabetes: systematic overview of prospective observational studies. Diabetologia 48: 2460-2469
274. Xu W, Qiu C, Winblad B, Fratiglioni L. 2007 The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56:211-216
275. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S, Kiyohara Y. 2011 Glucose tolerance status and risk of dementia in the community: The Hisayama Study. Neurology 77:1126-1134
276. Schrijvers EM, Witteman JC, Sijbrands EJ, Hofman A, Koudstaal PJ, Breteler MM. 2010 Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 75:1982-1987
277. Brüning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Müller-Wieland D, Kahn CR. 2000 Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122-2125
278. Marks JL, Porte Jr D, Stahl WL, Baskin DG. 1990 Localization of insulin receptor mRNA in rat brain by in situ hybridization. Endocrinology 127:3234-3236
279. Plata-Salamán CR. 1991 Insulin in the cerebrospinal fluid. Neurosci Biobehav Rev 15:243-258
280. Wozniak M, Rydzewski B, Baker SP, Raizada MK. 1993 The cellular and physiological actions of insulin in the central nervous system. Neurochem Int 22:1-10
281. Luo J, Becnel J, Nichols CD, Nässel DR. 2012 Insulinproducing cells in the brain of adult Drosophila are regulated by the serotonin 5-HT(1A) receptor. Cell Mol Life Sci 69:471-484
282. FridellYW, HohM, Kréneisz O, Hosier S, Chang C, Scantling D, Mulkey DK, Helfand SL. 2009 Increased uncoupling protein (UCP) activity in Drosophila insulin-producing neurons attenuates insulin signaling and extends lifespan. Aging (Albany NY) 1:699-713
283. Adamo M, Raizada MK, LeRoith D. 1989 Insulin and insulin-like growth factor receptors in the nervous system. Mol Neurobiol 3:71-100
284. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. 1995Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789
285. Phiel CJ, Wilson CA, Lee VM, Klein PS. 2003 GSK-3β regulates production of Alzheimer's disease amyloid-β peptides. Nature 423:435-439
286. Hooper C, Killick R, Lovestone S. 2008 The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104:1433-1439
287. Hoyer S. 2004 Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115-125
288. Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. 2011 Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. J Cell Mol Med 15:1807-1821
289. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. 2008 Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology 70:440-448
290. Dhamoon MS, Noble JM, Craft S. 2009 Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology 72:292-293; author reply 293-294
291. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B. 2012 Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69:29-38
292. Yamamoto N, Matsubara T, Sobue K, Tanida M, Kasahara R, Naruse K, Taniura H, Sato T, Suzuki K. 2012 Brain insulin resistance accelerates Ass fibrillogenesis by inducing GM1 ganglioside clustering in the presynaptic membranes. J Neurochem 121:619-628
293. Matsuzaki T, Sasaki K, Tanizaki Y, Hata J, Fujimi K, Matsui Y, Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T. 2010 Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75: 764-770
294. Begum AN, Yang F, Teng E, Hu S, Jones MR, Rosario ER, Beech W, Hudspeth B, Ubeda OJ, Cole GM, Frautschy SA. 2008 Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Aβ-infusion Alzheimer's disease model. J Alzheimers Dis 15: 625-640
295. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, Peng Y, Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM. 2004 Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18:902-904
296. Manolopoulos KN, Klotz LO, Korsten P, Bornstein SR, Barthel A. 2010 Linking Alzheimer's disease to insulin resistance: the FoxO response to oxidative stress. Mol Psychiatry 15:1046-1052
297. Mercado-Gómez O, Hernández-Fonseca K, Villavicencio-Queijeiro A, Massieu L, Chimal-Monroy J, Arias C. 2008 Inhibition of Wnt and PI3K signaling modulates GSK-3β activity and induces morphological changes in cortical neurons: role of tau phosphorylation. Neurochem Res 33: 1599-1609
298. de la Monte SM. 2009 Insulin resistance and Alzheimer's disease. BMB Rep 42:475-481
299. Tang C, Kanter JE, Bornfeldt KE, Leboeuf RC, Oram JF. 2010 Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J Lipid Res 51:1719-1728
300. Patel DC, Albrecht C, Pavitt D, Paul V, Pourreyron C, Newman SP, Godsland IF, Valabhji J, Johnston DG. 2011 Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function. PLoS One 6:e22142
301. Zhao WQ, Townsend M. 2009 Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792:482-496
302. de la Monte SM, Wands JR. 2008 Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2:1101-1113
303. Gupta A, Bisht B, Dey CS. 2011 Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60:910-920
304. Jiang Q, Heneka M, Landreth GE. 2008 The role of peroxisome proliferator-activated receptor-β (PPARβ) in Alzheimer's disease: therapeutic implications. CNS Drugs 22: 1-14
305. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S. 2005 Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950-958
306. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC, Zhao Y, Smith L, Gasparini L, Luo Z, Xu H, Liao FF. 2009 Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 106:3907-3912
307. McClean PL, Parthsarathy V, Faivre E, Hölscher C. 2011 The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci 31:6587-6594
308. Rivest S. 2009 Regulation of innate immune responses in the brain. Nat Rev Immunol 9:429-439
309. Yong VW, Rivest S. 2009 Taking advantage of the systemic immune system to cure brain diseases. Neuron 64:55-60
310. Nimmerjahn A, Kirchhoff F, Helmchen F. 2005 Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308:1314-1318
311. Combarros O, Infante J, Rodríguez E, Llorca J, Peña N, Fernández-Viadero C, Berciano .J 2005 CD14 receptor polymorphism and Alzheimer's disease risk. Neurosci Lett 380:193-196
312. Liu Y, Walter S, Stagi M, Cherny D, Letiembre M, Schulz-Schaeffer W, Heine H, Penke B, Neumann H, Fassbender K. 2005 LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. Brain 128:1778-1789
313. Fassbender K, Walter S, Kühl S, Landmann R, Ishii K, Bertsch T, Stalder AK, Muehlhauser F, Liu Y, Ulmer AJ, Rivest S, Lentschat A, Gulbins E, Jucker M, Staufenbiel M, Brechtel K, Walter J, Multhaup G, Penke B, Adachi Y, Hartmann T, Beyreuther K. 2004 The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J 18:203-205
314. Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE. 2010 Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. J Neurosci 30:15369-15373
315. Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG. 2009 Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 29:13435-13444
316. Akira S. 2001 Toll-like receptors and innate immunity. Adv Immunol 78:1-56
317. Kielian T. 2006 Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res 83:711-730
318. Chen K, Iribarren P, Hu J, Chen J, Gong W, Cho EH, Lockett S, DunlopNM, Wang JM. 2006 Activation of Tolllike receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid β-peptide. J Biol Chem 281:3651-3659
319. Richard KL, Filali M, Préfontaine P, Rivest S. 2008 Tolllike receptor 2 acts as a natural innate immune receptor to clear amyloidβ 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 28:5784-5793
320. Tahara K, Kim HD, Jin JJ, Maxwell JA, Li L, Fukuchi K. 2006 Role of toll-like receptor signalling in Aβ uptake and clearance. Brain 129:3006-3019
321. Reed-Geaghan EG, Savage JC, Hise AG, Landreth GE. 2009 CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation. J Neurosci 29:11982-11992
322. Fiala M, Liu PT, Espinosa-Jeffrey A, Rosenthal MJ, Bernard G, Ringman JM, Sayre J, Zhang L, Zaghi J, Dejbakhsh S, Chiang B, Hui J, MahanianM, Baghaee A, Hong P, Cashman J. 2007 Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc Natl Acad Sci USA 104:12849-12854
323. Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M, Ferrari D, Rossi F. 1995 Activation of microglial cells by β-amyloid protein and interferon-β. Nature 374:647-650
324. Tarkowski E, Blennow K, Wallin A, Tarkowski A. 1999 Intracerebral production of tumor necrosis factor-β, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol 19:223-230
325. Cacquevel M, Lebeurrier N, Chéenne S, Vivien D. 2004 Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 5:529-534
326. Ruan L, Kang Z, Pei G, Le Y. 2009 Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease. Curr Alzheimer Res 6:531-540
327. Quintanilla RA, Orellana DI, González-Billault C, Maccioni RB. 2004 Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway. Exp Cell Res 295:245-257
328. Hoshino T, Nakaya T, Homan T, Tanaka K, Sugimoto Y, Araki W, Narita M, Narumiya S, Suzuki T, Mizushima T. 2007 Involvement of prostaglandin E2 in production of amyloid-β peptides both in vitro and in vivo. J Biol Chem 282:32676-32688
329. Liang X, WangQ, HandT, WuL, BreyerRM, Montine TJ, Andreasson K. 2005 Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 25:10180-10187
330. Rivest S. 2011 The promise of anti-inflammatory therapies for CNS injuries and diseases. Expert Rev Neurother 11: 783-786
331. Tachida Y, Nakagawa K, Saito T, Saido TC, Honda T, Saito Y, Murayama S, Endo T, Sakaguchi G, Kato A, Kitazume S, Hashimoto Y. 2008 Interleukin-1 β up-regulates TACE to enhance β-cleavage of APP in neurons: resulting decrease in Aβ production. J Neurochem 104:1387-1393
332. Wilkinson BL, Landreth GE. 2006 The microglialNADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation 3:30
333. Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. 2010 Mechanisms underlying inflammation in neurodegeneration. Cell 140:918-934
334. Galimberti D, Scarpini E. 2011 Alzheimer's disease: from pathogenesis to disease-modifying approaches. CNS Neurol Disord Drug Targets 10:163-174
335. Peters C, Shapiro EG, Anderson J, Henslee-Downey PJ, Klemperer MR, Cowan MJ, Saunders EF, deAlarcon PA, Twist C, Nachman JB, Hale GA, Harris RE, Rozans MK, Kurtzberg J, Grayson GH, Williams TE, Lenarsky C, Wagner JE, Krivit W. 1998 Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty four children. The Storage Disease Collaborative Study Group. Blood 91:2601-2608
336. Naert G, Rivest S. 2011 The role of microglial cell subsets in Alzheimer's disease. Curr Alzheimer Res 8:151-155
337. Simard AR, Rivest S. 2006 Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry 11:327-335
338. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. 2006 Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49:489-502
339. Craft S. 2005 Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26(Suppl 1): 65-69
340. Freeman LR, Small BJ, Bickford PC, Umphlet C, Granholm AC. 7 March 2011 A high fat/high cholesterol diet inhibits growthof fetalhippocampaltransplants via increased inflammation. Cell Transplant 10.3727/096368910X557281
341. Zelcer N, Khanlou N, Clare R, Jiang Q, Reed-Geaghan EG, Landreth GE, Vinters HV, Tontonoz P. 2007 Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci USA 104: 10601-10606
342. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. 2000 Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7:321-331
343. Julien C, Tremblay C, Phivilay A, Berthiaume L, EmondV, Julien P, Calon F. 2010 High-fat diet aggravates amyloid-β and tau pathologies in the 3xTg-AD mouse model. Neurobiol Aging 31:1516-1531
344. Thirumangalakudi L, Prakasam A, Zhang R, Bimonte-Nelson H, Sambamurti K, Kindy MS, Bhat NR. 2008 High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J Neurochem 106:475-485
345. Fitz NF, Cronican A, PhamT, Fogg A, FauqAH, Chapman R, Lefterov I, Koldamova R. 2010 LiverXreceptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J Neurosci 30:6862-6872
346. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M. 2008 Cognitive function over time in the Alzheimer's Disease Anti-inflam-matory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896-905
347. Boissonneault V, Filali M, Lessard M, Relton J, Wong G, Rivest S. 2009 Powerful beneficial effects of macrophage colony-stimulating factor on β-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 132: 1078-1092
348. -/- mice. Gene Ther 18:835-841
349. Sun Y, Yao J, Kim TW, Tall AR. 2003 Expression of liver X receptor target genes decreases cellular amyloid β-peptide secretion. J Biol Chem 278:27688-27694
350. Riddell DR, Zhou H, Comery TA, Kouranova E, Lo CF, Warwick HK, Ring RH, Kirksey Y, Aschmies S, Xu J, Kubek K, Hirst WD, Gonzales C, Chen Y, Murphy E, Leonard S, Vasylyev D, Oganesian A, Martone RL, Pangalos MN, Reinhart PH, Jacobsen JS. 2007 The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol Cell Neurosci 34:621-628
351. Terwel D, Steffensen KR, Verghese PB, Kummer MP, Gustafsson JA, Holtzman DM, Heneka MT. 2011 Critical role of astroglial apolipoprotein E and liver X receptor-β expression for microglial Aβ phagocytosis. J Neurosci 31: 7049-7059
352. Donkin JJ, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S, Chan J, Fan J, Collins J, Wellington CL. 2010 ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem 285:34144-34154
353. Oosterveer MH, Grefhorst A, Groen AK, Kuipers F. 2010 The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design. Prog Lipid Res 49:343-352
354. Cermenati G, Abbiati F, Cermenati S, Brioschi E, Volonterio A, Cavaletti G, Saez E, De Fabiani E, Crestani M, Garcia-Segura LM, Melcangi RC, Caruso D, Mitro N. 2012 Diabetes-induced myelin abnormalities are associated with an altered lipid pattern: protective effects ofLXR activation. J Lipid Res 53:300-310